VivoSeq
Other

Apathy

14

Pipeline Programs↗

6

Active Trials↗

9

Companies Involved↗

Apathy is an emerging landscape with 14 programs across 9 companies. The most active players are Takeda, Glaxo Dba Glaxosmithkline, Novartis. 5 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

43/100

Pipeline Velocity

15/100

Mech. Concentration

30/100

Completion Rate

90/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Takeda logo

Takeda

1 program

Phase 1G

Glaxo Dba Glaxosmithkline

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2UCB logo

UCB

1 program

ApprovedEli Lilly logo

Eli Lilly

1 program

ApprovedInnovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

18

clinical trials

Completed9 · 50%
Recruiting4 · 22%
Unknown status2 · 11%
Not yet recruiting2 · 11%
Terminated1 · 6%

Clinical Trials

Trial Activity

18 trials

rTMS for Apathy Clinical Trial
Recruiting·SSunnybrook Health Sciences Centre·N/A·NCT05561205·10 enrolled
Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.
Recruiting·LLouisiana State University Health Sciences Center Shreveport·Phase 3·NCT06482554·80 enrolled
Safety and Tolerability of IRL757 in Participants With Parkinson's Disease and Apathy
Recruiting·IIntegrative Research Laboratories AB·Phase 1/2·NCT07461220·75 enrolled
Accelerated rTMS for Post-stroke Apathy: A Double-blind Randomized Controlled Trial
Recruiting·MMedical University of South Carolina·Preclinical·NCT07113067·40 enrolled
Methylphenidate for Apathy in Veterans With Parkinson's Disease
Not yet recruiting·—·Phase 2·NCT05669170·60 enrolled
The Volunteering-in-Place Program for Apathetic Assisted Living Residents With ADRD
Not yet recruiting·UUniversity of Maryland, Baltimore·Preclinical·NCT06735950·200 enrolled
Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy
Completed·UCB logoUCB·Phase 4·NCT01782222·122 enrolled
The Role of Apathy in Glycemic Control
Completed·US Department of Veterans Affairs·N/A·NCT00844090·106 enrolled
Apathy Associated With Alzheimer's Disease
Completed·SSunnybrook Health Sciences Centre·Phase 4·NCT00254033·40 enrolled
REmodelling in Diabetic CardiOmapathy: Gender Response to PDE5i InhibiTOrs
Completed·UUniversity of Roma La Sapienza·Phase 4·NCT01803828·120 enrolled
Treatment of Apathy in Alzheimer's Disease With Modafinil
Completed·—·Phase 3·NCT01172145·22 enrolled
Apathy Cure Through Bupropion in Huntington's Disease
Completed·—·Phase 2·NCT01914965·40 enrolled
Rasagiline and Apathy in Parkinson's Disease
Completed·FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau·Phase 4·NCT00755027·40 enrolled
Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System
Completed·IInstitut National de la Santé Et de la Recherche Médicale, France·N/A·NCT03272230·66 enrolled
Accelerated rTMS for Post-Stroke Apathy: Targeting Amotivation Toward Improving Whole Health and Rehabilitation Engagement
Completed·MMedical University of South Carolina·Phase 1·NCT05878457·21 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)